We are live on ! Find out more
Ken Griffin

Ken Griffin Citadel Advisors

AUM $618B
1-Year Est. Return 30.34%
 

Ken Griffin founded Citadel, one of the world’s largest and most successful hedge funds. Starting his trading career from his Harvard dorm room at a young age, Griffin quickly developed a keen sense for markets and built Citadel into a global powerhouse with billions in assets under management. Known for his quantitative and technology-driven strategies, Griffin has also made headlines for significant philanthropic contributions, supporting causes in education, the arts, and public institutions. Over the years, he has earned recognition as one of the preeminent figures in modern finance.

This Fund
S&P 500
This Quarter Est. Return
+6.7%
1 Year Est. Return
+30.34%
3 Year Est. Return
+94.87%
5 Year Est. Return
+105.94%
10 Year Est. Return
+434.06%
AUM
$164B
AUM Growth
+$34B
Cap. Flow
+$21.1B
Cap. Flow %
12.82%
Top 10 Hldgs %
19.02%
Holding
8,908
New
1,440
Increased
3,569
Reduced
2,696
Closed
988

Sector Composition

Rank Sector Weight
1 Technology 6.22%
2 Financials 6.16%
3 Industrials 5.09%
4 Consumer Discretionary 4.89%
5 Healthcare 4.54%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
PALI icon
7626
CALL
Palisade Bio
PALI
$375M
0
PRPH
7627
DELISTED
ProPhase Labs
PRPH
$26K ﹤0.01%
+1,182
New +$25.8K
RCG
7628
RENN Fund
RCG
$20.1M
$26K ﹤0.01%
17,250
+2,050
+13% +$2.89K
SGRP
7629
DELISTED
SPAR Group
SGRP
$26K ﹤0.01%
+21,154
New +$23.5K
SDR
7630
DELISTED
SANDRIDGE MISSISSIPPIAN TRUST II
SDR
$26K ﹤0.01%
+30,337
New +$36.1K
INFU icon
7631
InfuSystem Holdings
INFU
$249M
$25K ﹤0.01%
+10,946
New +$23.7K
LITB
7632
LightInTheBox
LITB
$56.7M
$25K ﹤0.01%
1,787
-292
-14% -$3.56K
CASM
7633
DELISTED
CAS Medical Systems, Inc.
CASM
$25K ﹤0.01%
+32,680
New +$23.9K
BLRX
7634
BioLineRX
BLRX
$11.7M
$24K ﹤0.01%
36
+17
+89% +$11.2K
DARE icon
7635
Dare Bioscience
DARE
$20.5M
$24K ﹤0.01%
+940
New +$30.2K
AGPU
7636
Axe Compute Inc
AGPU
$96M
$24K ﹤0.01%
+8
New +$34.8K
GRCE
7637
Grace Therapeutics
GRCE
$44.2M
$24K ﹤0.01%
541
-81
-13% -$5.44K
PHLT
7638
DELISTED
Performant Healthcare Inc
PHLT
$24K ﹤0.01%
+14,842
New +$26.8K
QUMU
7639
DELISTED
Qumu Corp.
QUMU
$24K ﹤0.01%
+10,614
New +$27.8K
BDR
7640
DELISTED
Blonder Tongue Laboratories Inc
BDR
$24K ﹤0.01%
+39,818
New +$19.1K
AST
7641
CALL
DELISTED
Asterias Biotherapeutics Inc. Series A
AST
$24K ﹤0.01%
10,500
-500
-5% -$1.27K
LTBR icon
7642
Lightbridge
LTBR
$333M
$23K ﹤0.01%
1,559
+267
+21% +$3.41K
THM
7643
International Tower Hill Mines
THM
$696M
$23K ﹤0.01%
54,096
+8,041
+17% +$3.45K
BYU
7644
DELISTED
BAIYU Holdings, Inc. Common Stock
BYU
$23K ﹤0.01%
+13
New +$48.1K
ATIS
7645
DELISTED
Attis Industries Inc. Common Stock
ATIS
$23K ﹤0.01%
2,726
+765
+39% +$7.11K
CVRS
7646
DELISTED
CORINDUS VASCULAR ROBOTICS, INC
CVRS
$23K ﹤0.01%
+22,980
New +$26K
YGE
7647
PUT
DELISTED
Yingli Green Energy Holding Comp
YGE
$23K ﹤0.01%
+13,400
New +$28.4K
FCRE
7648
DELISTED
FC Global Realty Incorporated Common Stock
FCRE
$23K ﹤0.01%
+24,634
New +$27.2K
PRPO icon
7649
Precipio
PRPO
$40.3M
$22K ﹤0.01%
+61
New +$27.5K
SEEL
7650
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
0

Similar funds

Ken Griffin's Q4 2017 Portfolio in Review

As of Q4 2017, Ken Griffin held 8,908 positions worth $164B, up 26% from $130B the previous quarter. Its ten largest holdings account for 19% of the portfolio.

Ken Griffin deployed $21.1B of net new capital in Q4 2017, opening 1,440 new positions and adding to 3,569 existing holdings. Its largest new stake was Celgene Corp: 3,708,916 shares worth $387M.

By sector, the portfolio is most concentrated in Technology at 6.2% of assets, down from 7.2% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was Goldman Sachs, an estimated $441M trimmed.

  • Ken Griffin's largest Q4 2017 buy was Celgene Corp: 3,708,916 shares worth $387M.
  • Ken Griffin added most to State Street SPDR S&P 500 ETF Trust in Q4 2017, an estimated $1.16B increase.
  • Ken Griffin's biggest Q4 2017 reduction was Goldman Sachs, cutting an estimated $441M.
  • Ken Griffin fully exited CR Bard Inc. in Q4 2017, selling an estimated $209M.
  • Ken Griffin's ten largest holdings make up 19% of its $164B portfolio in Q4 2017.
  • Ken Griffin opened 1,440 new positions and closed 988 in Q4 2017.
  • Ken Griffin's portfolio value rose 26% quarter-over-quarter to $164B.

Based on Citadel Advisors's 13F filing for Q4 2017, filed 9 Feb 2018.